82958
EPN · Supratentorial EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Supratentorial EPN
- cancer_type
- EPN
- subtype
- Supratentorial EPN
- age_years
- 2
- fusion
- ZFTA_RELA
- e1_e2
- E1
- umap1_2d
- -2.843395295
- umap2_2d
- 1.33998161
- umap1_3d
- 0.259810618
- umap2_3d
- 3.305782341
- umap3_3d
- -2.444488085
- dataset
- EPN-Felix
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.350
- G2M_CHECKPOINT+0.350
- NOTCH_SIGNALING+0.320
- DNA_REPAIR+0.290
- MITOTIC_SPINDLE+0.290
- WNT_BETA_CATENIN_SIGNALING+0.230
- OXIDATIVE_PHOSPHORYLATION+0.220
- MYC_TARGETS_V1+0.190
- UV_RESPONSE_DN+0.120
- PI3K_AKT_MTOR_SIGNALING+0.090
Top 10 suppressed
- INFLAMMATORY_RESPONSE-0.440
- HYPOXIA-0.430
- ALLOGRAFT_REJECTION-0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.400
- ANGIOGENESIS-0.370
- TNFA_SIGNALING_VIA_NFKB-0.370
- INTERFERON_GAMMA_RESPONSE-0.360
- IL2_STAT5_SIGNALING-0.350
- COAGULATION-0.340
- MTORC1_SIGNALING-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD030469_D1.RNA-Seq | EPN | Supratentorial EPN | 0.904 |
| 2 | SJEPD031592_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.856 |
| 3 | MNG953 | — | — | 0.845 |
| 4 | SAMN03290891 | — | — | 0.837 |
| 5 | TCGA-OR-A5K4-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.826 |
| 6 | TCGA-43-7658-01A-11R-2125-07 | — | cohortMD1 | 0.826 |
| 7 | MDT-AP-0156 | Med | Medulloblastoma | 0.825 |
| 8 | 23b70cde-f829-473b-b253-fd87eef7605f | — | — | 0.824 |
| 9 | BS_HTEPAKCM | medulloblastoma | — | 0.823 |
| 10 | MNG239 | — | — | 0.823 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.350 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.350 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.320 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.290 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.290 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.230 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.220 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.190 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.120 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.090 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.060 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.040 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.010 | Temsirolimus | — uncovered |
| PANCREAS_BETA_CELLS | 0.010 | Cobimetinib | — uncovered |